Clinical Trial Update: Autoantibodies Against Human Recombinant Erythropoietin in Myelodysplatic Syndrome Patients

View source ↗

Summary

An update on a clinical trial evaluating autoantibody formation against recombinant human erythropoietin in patients with myelodysplastic syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: yair levy | Conditions: Myelodysplatic Syndrome | Status: UNKNOWN